High-throughput screening identifies radioprotectors and radiomitigators — compounds that protect cells from ionizing radiation damage (nuclear, space, radiotherapy) targeting DNA double-strand break repair, ROS scavenging, and p53-pathway modulation
Ionizing radiation — gamma rays, X-rays, proton beams, and heavy ions — deposits energy in biological tissue through processes that produce DNA breaks, oxidative stress, and cell death. Understanding the physics of energy deposition and the biology of DNA damage response at the molecular level is essential for developing effective countermeasures to protect astronauts, radiation accident victims, and cancer patients receiving radiotherapy.
Radiation types and interactions:
1. Electromagnetic radiation (gamma/X-rays): • Gamma: emitted from radioactive decay (⁶⁰Co 1.25 MeV, ¹³⁷Cs 662 keV) • Primary interaction: Compton scattering (0.1–1 MeV), photoelectric effect (<0.1 MeV) • Compton: incident photon knocks electron from atom → recoil electron ionizes further • Electron range: 1–10mm in tissue → diffuse ionization along track • Linear energy transfer (LET): gamma ~0.2 keV/µm (low LET) → sparsely ionizing
2. Proton radiation: • Used in proton beam therapy: 150–250 MeV protons • Bragg peak: proton loses energy gradually → deposits maximum energy at range end • Advantage for therapy: Bragg peak at tumor; minimal dose beyond • LET: 1–5 keV/µm in tissue; rises near end of range (~80 keV/µm Bragg peak)
3. Heavy ions (HZE particles in space): • Galactic cosmic rays: Fe-56 at ~1 GeV/nucleon; LET ~150–200 keV/µm • High LET → dense ionization track → clustered DNA damage (2–3 DSBs within 1–2nm) • Clustered damage: extremely difficult for repair enzymes to resolve • RBE (relative biological effectiveness): RBE = LET(reference)/LET_test for same effect Fe-56 RBE = 15–30 for cell killing vs. gamma • Shielding: paradoxically, heavy nuclei can produce secondary spallation particles increasing low LET fluence → aluminum shielding can worsen situation
4. Neutrons: • Indirect ionizers: scatter H nuclei → proton recoils ionize tissue • Fast neutrons (>1 MeV): proton recoils; LET 10–20 keV/µm • Thermal neutrons: captured by ¹⁴N → ¹⁴C + proton; activation of stable nuclei
DNA damage types per 1 Gy gamma irradiation: • Double-strand breaks (DSBs): ~40 per cell (both helical strands broken within <10 bp) • Single-strand breaks (SSBs): ~1,000 per cell (repaired 99.9% in <30 min) • Base damage: ~3,000 per cell (oxidized guanine, abasic sites) • DNA-protein crosslinks: ~150 per cell • Clustered damage (from high LET): 2–5 DSBs within ~10nm → "complex DSBs" Complex DSBs significantly more lethal than isolated DSBs
DNA damage:lethality relationship: • LD₅₀/30 (humans without treatment): 3.5–4.5 Gy whole-body • If all DSBs unrepaired: ~40 × 3.5Gy = 140 DSBs per cell ≡ lethal (consistent with 1-3 unrepaired DSBs per cell being lethal) • Cells that survive repair all DSBs within 24–48h • Misrepaired DSBs: chromosomal translocations, deletions → carcinogenesis in survivors
Approximately 70% of radiation damage to cells is "indirect" — mediated not by the radiation track itself, but by free radicals produced when X-rays or gamma rays split water molecules. The resulting hydroxyl radical is among the most reactive chemical species in biology, capable of abstracting hydrogen atoms from nearby molecules in nanoseconds. Understanding this chemistry is the key to designing antioxidant radioprotectors.
Water radiolysis — primary events (picoseconds):
Primary radiolysis products: • H₂O + γ → H₂O⁺ + e⁻_aq (ionization) → H₂O* (excitation) • H₂O⁺ + H₂O → OH• + H₃O⁺ (ion-molecule reaction; <10 ps) • H₂O* → H• + OH• (bond homolysis; ~10 ps) • e⁻_aq → solvated electron (thermalization; ~1 ps)
Reactive species G-values (molecules/100 eV absorbed): • OH•: 2.8; H•: 0.6; e⁻_aq: 2.7; H₂O₂: 0.7; H₂: 0.45
Secondary reactions (nanoseconds to microseconds): • OH• + OH• → H₂O₂ • e⁻_aq + O₂ → O₂•⁻ (superoxide, if O₂ present) • O₂•⁻ + H• → HO₂• (hydroperoxyl radical)
Oxygen enhancement effect: • Key: O₂ + DNA radical (R•) → RDOO• (peroxy radical) → irreversible damage • Without O₂: R• → back-reaction with H• → repair (chemical repair) • Oxygen enhancement ratio (OER): dose without O₂ / dose with O₂ for same effect = 2.5–3.0 for gamma • Hypoxic tumors: resistant to radiation → clinical challenge in radiotherapy
Lipid peroxidation chain reaction: • Initiation: OH• + polyunsaturated fatty acid (PUFA) → lipid radical (L•) + H₂O • Propagation: L• + O₂ → LOO• → LOOH + L•(new) → chain reaction • Termination: LOO• + LOO• → non-radical products (tocol scavengers interrupt) • 1 OH• can initiate thousands of lipid peroxidations → membrane destruction
Antioxidant radioprotection mechanisms:
1. Thiol scavengers (cytoprotective thiols): • Amifostine (WR-2721): prodrug → dephosphorylated by alkaline phosphatase → WR-1065 (free thiol) • WR-1065 (HS-CH₂-CH₂-NH-CH₂-CH₂-CH₂-NH₂): a) H-donation: R• + WR-1065 → RH + WR-thiol radical (chemical repair) b) OH• scavenging: OH• + WR-1065 → H₂O + thiol radical (diffusion controlled) c) Radical translocation: moves radical from DNA to WR-1065 • Factor 2.4× dose reduction = DRF 2.4 (most effective known radioprotector)
2. Mn-porphyrin SOD mimetics (AEOL 10150): • Superoxide dismutase (SOD) mimic: O₂•⁻ + O₂•⁻ + 2H⁺ → H₂O₂ + O₂ • Mn(III) porphyrin: catalytic antioxidant; SOD + ONOO⁻ scavenging + peroxidase activity • Key advantage over SOD enzyme: crosses cell membranes + reaches mitochondria • DRF: 1.8–2.0 (post-exposure treatment — true radiomitigator, not protector)
3. Radioprotective gene expression inducers: • NF-κB activators: induce antioxidant response element (ARE) genes → catalase, SOD, Nrf2 • NLGN1/Ex-Rad: activates PI3K-Akt survival signaling + increases catalase expression • JPY-7 (JP Pharma): HIF-1α activator → pre-adapts cells to oxidative stress
4. p53 inhibitor pifithrin-α: • Temporarily block p53-mediated apoptosis in normal tissue (radio-normal cells) • Tumor: p53 often mutated → pifithrin-α effect on tumor cells minimal • Strategy: protect normal tissue while leaving tumor radiation-sensitive • Concern: carcinogenesis risk from surviving damaged cells
Within minutes of ionizing radiation exposure, the cell activates an elegant molecular alarm system centered on a single protein: H2AX, a histone variant. When kinase ATM detects a double-strand break, it phosphorylates H2AX at serine-139 in megabase-pair domains flanking the break, creating a visible focus of γH2AX detectable by immunofluorescence. Counting these foci in exposed cells provides a direct measure of DNA damage and repair kinetics — now used for radiation dosimetry, drug safety testing, and countermeasure screening.
DNA double-strand break sensing and signaling:
1. MRN complex — break recognition: • Mre11 (double-strand DNA binding) + Rad50 (coiled-coil, ATP hydrolysis) + Nbs1 (ATM recruiter) • MRN binds DSB ends within seconds (TIRFM live imaging shows <5s) • Activates ATM (ataxia telangiectasia mutated) kinase (PI3K-family) • ATM: monomer at chromatin → DSB → dimer → rapid autophosphorylation S1981 → active monomer
2. H2AX phosphorylation — focal amplification: • ATM phosphorylates H2AX (histone variant, 10–15% of total H2A) at Ser139 → γH2AX • Phosphorylation spreads: ~1,000 γH2AX molecules per DSB in 1–2 Mbp domain • Mechanism: ATM diffuses along chromatin fiber → phosphorylates H2AX until boundaries • Boundaries: insulator elements (CTCF binding sites) stop spreading in some cell types • Visualization: anti-γH2AX antibody (JBW301, Sigma) + secondary fluorescent antibody Confocal microscopy: 1 bright focus = 1 DSB; automated counting possible
3. DAD complex assembly at foci: • MDC1 (mediator of DDR) → binds γH2AX directly via BRCT domains → scaffold • RNF8 ubiquitin ligase → ubiquitinates H1 → K63-ubiquitin chain → recruits RNF168 • RNF168 → ubiquitinates H2A K13, K15 → recruits BRCA1-BARD1 • PALB2 → BRCA2 → RAD51 (pathway choice: HR vs. NHEJ)
4. DSB repair pathways:
a) Non-Homologous End Joining (NHEJ) — fast, error-prone: • Active in G1, S, G2 (constitutive) • Ku70/Ku80 hetrodimer: binds DNA ends (high affinity, Kd ~10⁻⁹M) → synapses ends • DNA-PKcs (largest kinase, 469 kDa) → activated by Ku-DNA → phosphorylates Artemis • Artemis nuclease: hairpin opening + overhang trimming → blunt ends • X4-Lig4 complex: ligates DNA ends → complete • Speed: <1 hour per DSB; majority of DSBs repaired by NHEJ • Error: often deletes 1–10 bp at junction → mutations at repair site
b) Homologous Recombination (HR) — slow, accurate: • Active only in S/G2 phase (sister chromatid available as template) • 5'→3' resection: MRN + CtIP → generate 3'-ssDNA overhang • RPA coating → replaced by RAD51 (catalyzed by BRCA2) • RAD51 filament: strand invasion of sister chromatid → D-loop • DNA synthesis: uses sister as template → accurate restoration • Speed: 6–24 hours; only used for ~15–20% of DSBs
5. Cell cycle checkpoints: • G1/S checkpoint: ATM → Chk2 → Cdc25A degradation → CDK2-cyclinE inhibition → arrest Maintains for ~12h; allows time for NHEJ repair • Intra-S checkpoint: ATM → SMC1 phosphorylation → slows replication fork firing • G2/M checkpoint: ATM/ATR → Chk1/Chk2 → phosphorylate Cdc25C → 14-3-3 sequestration → CDK1 inhibition G2 arrest: prevents mitosis with unrepaired DSBs → chromosome segregation catastrophe prevented • Checkpoint abrogation drugs: UCN-01 (CHK1 inhibitor), AZD7762 → force cells into mitosis → increase DSB lethality → radiosensitization of cancer cells
6. γH2AX as biomarker: • Biodosimetry: blood sample → γH2AX foci in lymphocytes → radiation dose estimate • Resolution kinetics: foci disappear as DSBs repaired → >75% foci in 24h = NHEJ complete • Persistent foci (>24h): complex DSBs (HZE track) or misrepair → chromosomal aberrations • Drug screening use: compare γH2AX foci (damaged + drug) vs. (damaged + vehicle) → select compounds that reduce foci
High-throughput screening (HTS) for radioprotectors or radiomitigators requires both a reliable radiation source affordable for a core facility and a quantitative cell viability or DNA damage readout compatible with miniaturized well-plate format. From assay development through Z-prime optimization to primary screen data analysis, the HTS platform for radiation countermeasures has distinct challenges: the radiation must be applied to all wells simultaneously, and the timing of compound addition relative to irradiation determines whether you find protectors (pre) or mitigators (post).
Radiation countermeasure HTS assay design:
1. Radiation sources compatible with 384-well HTS:
a) Cesium-137 (¹³⁷Cs) gamma irradiator: • Gammacell®440: cylindrical source; automated rotation for dose uniformity • Dose rate: 1–10 Gy/min (adjustable time); dose uniformity ±5% across plate • Advantage: standard in radiobiology labs; well-characterized • Disadvantage: radioactive source (NRC license); uniform dose only (no spatial control)
b) X-ray irradiator (RS2000/X-RAD 320): • No radioactive license; push-button operation; 320kVp X-ray tube • Dose rate: 1–3 Gy/min; well compatible; non-parallel beams → ±3% uniformity across plate • Best for routine HTS: commercially available; biosafety cabinet-compatible
c) Proton/heavy ion beamline: • Cyclotron facility (NIRS Japan, NASA Space Radiation Lab NSRL, GSI Germany) • Required for HZE particle screening (space radiation relevant) • Limited availability: 1–2 plates per beam time allocation; expensive • Important for: testing countermeasures against HZE damage (NASA-funded)
2. Cell-based assay formats:
a) CellTiter-Glo 2.0 (Promega) — luminescent ATP viability: • Principle: firefly luciferase converts ATP to AMP + light (560nm); ATP ∝ cell number • Incubation after radiation: 24h (acute cell death) or 72h (clonogenic fraction) • Limitations: detects any ATP-consuming/producing effect of compound → false positives from mitochondrial modulators • Z' factor: typically 0.7–0.85 using 0Gy vs. 8Gy controls
b) Crystal violet clonogenic assay (miniaturized): • Gold standard for radiation cell killing: measures surviving colony-forming cells • Miniaturized to 96-well plate: plate 200 cells/well → irradiate → fix/stain 10d later • Count colonies (>50 cells) per well → surviving fraction • Impractical for primary HTS (10-day readout, manual counting) • Used for hit validation after primary screen
c) γH2AX immunofluorescence (IF) imaging: • Plate 7,000 cells/well (384-well) → irradiate → fixation 1h post → anti-γH2AX (Alexa 488) + DAPI • Automated imaging (OperaPhenix or ImageXpress): count γH2AX foci per nucleus • Radioprotector criterion: fewer γH2AX foci vs. vehicle control → direct DNA damage readout • Challenge: >5σ below compound concentration that reduces DSBs by cytotoxicity alone • Throughput: 1 plate = 2h imaging + 2h analysis (automated) → 2,000 compounds/week
3. Assay quality metrics:
Z' factor = 1 - 3(σ_pos + σ_neg) / |µ_pos - µ_neg| • Z' > 0.5: acceptable for primary HTS • Z' > 0.7: excellent assay quality • Z' < 0: assay window too small (sigma overlap)
Signal window = (µ_pos - µ_neg) / σ_neg • >3: acceptable; >10: excellent
Acceptance criteria per plate: • Coefficient of variation (CV) within plate <15% for DMSO control wells • All controls within ±3σ of mean → no plate artifacts
4. Hit identification and confirmation: • Primary screen cutoff: >2σ above DMSO mean = primary hit • Typical hit rate: 0.01–0.1% (50–1,000 hits per 1M compound library) • Follow-up: dose-response curve (8 concentrations) → IC50/EC50 • Orthogonal assay: different readout (γH2AX if primary was ATP) → eliminates false positives • Mechanism triage: ROS scavenger (DPPH assay), cell cycle modulators (flow cytometry), direct DNA radical scavenging (comet assay)
5. DRF measurement: • Dose survival curves: irradiate cells at 0,1,2,4,6,8 Gy ± compound • Fit: linear-quadratic model: SF = exp(-(αD + βD²)) • DRF = dose for 50% survival (compound) / dose for 50% survival (vehicle) • DRF > 1 = radioprotection; DRF > 2 = significant • Best approved agent: Amifostine DRF = 2.4–2.7 in vivo (mouse)
Identifying a compound that reduces γH2AX foci in a 384-well plate assay is only the beginning of the countermeasure development journey. Translating a cell-based screen hit to an approved medical countermeasure requires demonstrating dose-reduction in vivo, proving the compound does not protect tumor cells in radiotherapy contexts, characterizing absorption-distribution-metabolism-excretion (ADME), and navigating a unique regulatory pathway under the FDA Animal Rule.
Lead countermeasure optimization pipeline:
1. Hit-to-lead optimization criteria: • DRF > 1.5 in cells at non-toxic concentration • No tumor radioprotection (selectivity test: irradiate tumor cell lines in same assay) • Solubility: >100 µg/mL at DMSO<0.1% → oral or IV formulation feasible • Metabolic stability: t½ >60 min in human liver microsomes (HLM) • hERG: IC50 >10µM (no cardiac liability) • Ames test: non-mutagenic (essential — radioprotectors must not be themselves mutagenic)
2. Synthetic medicinal chemistry iterations: • Structure-activity relationships (SAR): systematically vary substituents • Amifostine analogues (thiol prodrugs): - Extend alkyl chain between thiol and amine → change tissue distribution - N,N-dimethyl analogues → slower alkaline phosphatase dephosphorylation → prolonged action - Problem: all WR-series thiols cause nausea (dose-limiting toxicity at clinical DRF doses) • Mn-porphyrin improvements: - AEOL 10150 vs. AEOL 10113: side chain substitution → improved pharmacokinetics - BBB penetration: critical for CNS protection (astronaut CNS damage prevention) - Amphipathic variants: mitochondrial targeting (cardiolipin oxidation = key radiation target)
3. In vivo radiation models:
a) Acute radiation syndrome (ARS) mouse model: • C57BL/6J mice; whole-body X-ray or ¹³⁷Cs gamma; LD50/30 = 7.5–8.5 Gy • Drug given: 30 min before exposure (protector) or 24h after (mitigator) • Endpoint: 30-day survival; probit analysis: dose-response → LD50 shift = DRF • Amifostine: DRF = 2.4 (protects mice against 2.4× LD50 vs. vehicle) • AEOL 10150: DRF = 1.8 (given post-exposure) → first post-exposure mitigator
b) Hematopoietic syndrome sublethal irradiation: • White blood cell nadir: 10 days post-exposure; recovery 4–6 weeks • CBC (complete blood count) kinetics: radioprotector accelerates neutrophil recovery → reduces infection • Cytokine countermeasures: G-CSF (filgrastim), GM-CSF (sargramostim) → FDA approved for hematopoietic ARS (not classical radioprotectors; stimulate HSC recovery)
c) GI syndrome model: • High dose (15–20 Gy): kills intestinal crypts → diarrhea/dehydration/death day 4–6 • Endpoint: intestinal crypt survival (microcolony assay) • AEOL 10150: protects gut endothelium from radiation-induced fibrosis (delayed GI injury model)
4. FDA Animal Rule (21 CFR 314.600): • Used when human efficacy trials are unethical (nuclear countermeasures) • Requirements: a) Established animal model that reasonably correlates with human response b) Efficacy demonstrated in at least 2 species (mouse + nonhuman primate preferred) c) Human pharmacokinetics established (Ph1 safety trial in healthy volunteers) d) Biomarker: animal PK/PD correlates with human PK → bridge dose • Nelarabine (approved 2005): first drug via Animal Rule; aplastic anemia • Challenge: NHP (non-human primate) studies are expensive, time-consuming (6-month survival) • BARDA (Biomedical Advanced Research and Development Authority) funds medical countermeasure development
5. Current pipeline and space radiation countermeasures:
Approved (FDA): • Amifostine: DRF 2.4; protects against cisplatin nephrotoxicity AND radiation • G-CSF (Neupogen)/GM-CSF (Leukine): hematopoietic recovery • DTPA (Zn-DTPA/Ca-DTPA): chelation for internal radioactive contamination (Pu, Am, Cm)
Clinical/advanced stage: • AEOL 10150: Phase 1 complete (2023); pulmonary fibrosis indication; BARDA-funded • Ex-Rad (ON 01210.Na): Phase 2 complete in healthy volunteers; DRF 2.1 post-exposure • BIO 300 (genistein nanosuspension): Phase 2 ongoing (genitourinary radiation protection)
NASA-specific pipeline: • Space radiation: <1% iron HZE but very high RBE; focus on CNS protection • Targets: neuroinflammation (NAC = N-acetylcysteine trials), cognitive protect • Melatonin high-dose: antioxidant; crew taking personal during solar particle events • Genetic countermeasures: DNA repair overexpression (Rad51, BRCA2 gene therapy) — long-term research
BIO 300, a nanoformulation of genistein (soy isoflavone), has advanced to Phase 2 clinical trials as a radiation countermeasure for genitourinary cancer patients. It demonstrates DRF of 1.6–1.9 in mouse models when administered 24h before radiation, and uniquely, it does not protect tumor cells — making it a safer adjunct to radiotherapy than Amifostine. BARDA has committed $71 million to its development as a strategic national stockpile medical countermeasure for nuclear emergencies.